CSF TAU PROTEIN: A NEW PROGNOSTIC MARKER FOR GUILLAIN-BARRE SYNDROME

Neurology ◽  
2007 ◽  
Vol 68 (17) ◽  
pp. 1438-1439
Author(s):  
A. Asbury ◽  
A. Takeda ◽  
K. Jin ◽  
S. Kusunoki ◽  
Y. Itoyama
Neurology ◽  
2006 ◽  
Vol 67 (8) ◽  
pp. 1470-1472 ◽  
Author(s):  
K. Jin ◽  
A. Takeda ◽  
Y. Shiga ◽  
S. Sato ◽  
A. Ohnuma ◽  
...  

1992 ◽  
Vol 31 (5) ◽  
pp. 574-575 ◽  
Author(s):  
J. C. Ruiz ◽  
J. Berciano ◽  
J. M. Polo ◽  
A. L. M. de Francisco ◽  
M. Arias

Neurology ◽  
2006 ◽  
Vol 67 (6) ◽  
pp. 1071-1073 ◽  
Author(s):  
A. Petzold ◽  
N. Hinds ◽  
N. F. Murray ◽  
N. P. Hirsch ◽  
D. Grant ◽  
...  

2008 ◽  
Vol 38 (1) ◽  
pp. 899-903 ◽  
Author(s):  
Francesca Notturno ◽  
Christina M. Caporale ◽  
Angelo De Lauretis ◽  
Antonino Uncini

2022 ◽  
Vol 12 ◽  
Author(s):  
Qiuling Zang ◽  
Yating Wang ◽  
Junshuang Guo ◽  
Liyang Long ◽  
Shuyu Zhang ◽  
...  

A severely comatose female patient was diagnosed with Japanese encephalitis (JE). Her condition was complicated by Hashimoto’s thyroiditis (HT) and Guillain-Barré syndrome (GBS). After antiviral, glucocorticoid, and immunoglobulin treatment, the patient’s consciousness was restored, and she could breathe spontaneously. Following this, new-onset, primarily demyelinating GBS developed, which progressed to demyelination combined with axonal injury. The patient was switched to protein A immunoadsorption (PAIA) therapy, and her Hughes score decreased rapidly, from 4 to 1 after 6 months. This patient is the first to receive PAIA combined with an antiviral-glucocorticoid-immunoglobulin regimen to treat encephalitis, meningitis, HT, and GBS caused by JE infection, thereby reflecting the importance of clinical application of PAIA in the treatment of immunological complications of JE.


Sign in / Sign up

Export Citation Format

Share Document